Orion Oyj Logo

Orion Oyj

ISIN: FI0009014369 | Ticker: ORNAV | LEI: 74370029VAHCXDR7B745
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Finland

About Orion Oyj

Company Description

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain.

Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group.

Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets and a few Southeast Asian countries. In other markets Orion’s products are sold by several collaboration partners.

Served area

Worldwide

Headquarters

Orionintie 1A, 2200 Espoo – Finland

Financial statements

Download as Excel
Line item in (eur) 02.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 1,035,700,000.00 1,115,600,000.00 1,114,000,000.00 1,503,600,000.00
Noncurrent Assets N/A 435,600,000.00 371,800,000.00 423,700,000.00 624,900,000.00
Property Plant And Equipment N/A 320,900,000.00 319,600,000.00 332,600,000.00 373,300,000.00
Goodwill N/A 13,500,000.00 13,500,000.00 13,500,000.00 87,200,000.00
Copyrights Patents And Other Industrial Property Rights Service And Operating Rights N/A 34,800,000.00 26,800,000.00 53,000,000.00 100,000,000.00
Other Intangible Assets N/A 2,800,000.00 2,700,000.00 2,500,000.00 3,800,000.00
Investments In Associates Accounted For Using Equity Method N/A 100,000.00 100,000.00 100,000.00 100,000.00
Other Noncurrent Receivables N/A 800,000.00 500,000.00 300,000.00 1,000,000.00
Deferred Tax Assets N/A 6,800,000.00 8,400,000.00 6,600,000.00 3,100,000.00
Noncurrent Recognised Assets Defined Benefit Plan N/A 55,800,000.00 N/A 15,000,000.00 56,200,000.00
Noncurrent Investments Other Than Investments Accounted For Using Equity Method N/A 200,000.00 200,000.00 200,000.00 200,000.00
Current Assets N/A 600,100,000.00 743,700,000.00 690,300,000.00 878,700,000.00
Inventories N/A 230,300,000.00 258,100,000.00 265,200,000.00 315,600,000.00
Current Trade Receivables N/A 196,500,000.00 157,400,000.00 174,800,000.00 180,700,000.00
Other Current Receivables N/A 24,300,000.00 33,900,000.00 30,200,000.00 44,800,000.00
Current Tax Assets Current N/A N/A N/A 3,300,000.00 4,900,000.00
Cash and cash equivalents N/A 114,000,000.00 294,400,000.00 216,700,000.00 332,600,000.00
Equity And Liabilities N/A 1,035,700,000.00 1,115,600,000.00 1,114,000,000.00 1,503,600,000.00
Equity 772,900,000.00 779,400,000.00 731,300,000.00 747,900,000.00 908,100,000.00
Issued Capital N/A 92,200,000.00 92,200,000.00 92,200,000.00 92,200,000.00
Retained Earnings N/A 684,200,000.00 635,700,000.00 N/A N/A
Other Reserves N/A 3,000,000.00 3,400,000.00 N/A N/A
Equity Attributable To Owners Of Parent N/A 779,400,000.00 731,300,000.00 747,900,000.00 908,100,000.00
Liabilities N/A 256,300,000.00 384,200,000.00 366,100,000.00 595,500,000.00
Noncurrent Liabilities N/A 68,800,000.00 170,100,000.00 156,900,000.00 320,200,000.00
Noncurrent Provisions N/A 400,000.00 400,000.00 400,000.00 N/A
Other Longterm Provisions N/A N/A N/A 400,000.00 600,000.00
Deferred Tax Liabilities N/A 41,200,000.00 29,300,000.00 34,000,000.00 42,200,000.00
Noncurrent Recognised Liabilities Defined Benefit Plan N/A 3,400,000.00 19,900,000.00 4,900,000.00 3,000,000.00
Other Noncurrent Liabilities N/A 17,100,000.00 15,000,000.00 13,000,000.00 77,700,000.00
Longterm Borrowings N/A 6,700,000.00 105,500,000.00 104,700,000.00 196,800,000.00
Current Liabilities N/A 187,500,000.00 214,100,000.00 209,200,000.00 275,400,000.00
Current Provisions N/A N/A N/A 0.00 100,000.00
Trade And Other Current Payables To Trade Suppliers N/A 79,000,000.00 86,700,000.00 89,600,000.00 114,400,000.00
Current Tax Liabilities Current N/A 2,600,000.00 2,500,000.00 6,800,000.00 1,400,000.00
Other Current Liabilities N/A 102,600,000.00 121,800,000.00 109,000,000.00 142,400,000.00
Line item in (eur) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 1,051,000,000.00 1,078,100,000.00 1,041,000,000.00 1,340,600,000.00
Employee Benefits Expense 217,100,000.00 227,000,000.00 231,000,000.00 N/A
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 56,100,000.00 56,500,000.00 45,800,000.00 N/A
Profit Loss From Operating Activities 252,800,000.00 280,100,000.00 243,300,000.00 439,600,000.00
Finance Income 700,000.00 200,000.00 N/A N/A
Finance Costs 2,600,000.00 2,000,000.00 N/A N/A
Profit Loss Before Tax 250,800,000.00 278,300,000.00 242,300,000.00 440,300,000.00
Income Tax Expense Continuing Operations 50,500,000.00 58,400,000.00 48,500,000.00 90,800,000.00
Profit (loss) 200,400,000.00 219,900,000.00 193,800,000.00 349,500,000.00
Profit Loss Attributable To Owners Of Parent 200,400,000.00 219,900,000.00 193,800,000.00 349,500,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) 200,400,000.00 219,900,000.00 193,800,000.00 349,500,000.00
Adjustments For Reconcile Profit Loss 58,700,000.00 58,200,000.00 50,200,000.00 113,600,000.00
Adjustments For Decrease Increase In Inventories -8,000,000.00 -29,000,000.00 -6,900,000.00 -4,100,000.00
Adjustments For Provisions 0.00 0.00 100,000.00 200,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains -400,000.00 700,000.00 -400,000.00 400,000.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets N/A 0.00 -3,900,000.00 -100,000.00
Other Adjustments To Reconcile Profit Loss 600,000.00 1,300,000.00 1,400,000.00 63,600,000.00
Adjustments For Reconcile Profit Loss 58,700,000.00 58,200,000.00 50,200,000.00 113,600,000.00
Dividends Received Classified As Operating Activities 0.00 0.00 0.00 0.00
Cash Flows From Used In Operating Activities 270,800,000.00 299,100,000.00 215,700,000.00 434,400,000.00
Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities 1,400,000.00 N/A N/A N/A
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A N/A N/A 82,000,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 28,700,000.00 34,000,000.00 47,000,000.00 56,500,000.00
Purchase Of Intangible Assets Classified As Investing Activities 7,500,000.00 6,700,000.00 38,000,000.00 16,600,000.00
Cash Flows From Used In Investing Activities -34,000,000.00 -39,700,000.00 -80,200,000.00 -154,300,000.00
Payments To Acquire Or Redeem Entitys Shares 7,400,000.00 N/A N/A 17,900,000.00
Dividends Paid Classified As Financing Activities 211,200,000.00 211,100,000.00 211,200,000.00 211,200,000.00
Cash Flows From Used In Financing Activities -371,400,000.00 -115,100,000.00 -214,800,000.00 -159,800,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes -134,500,000.00 144,300,000.00 -79,300,000.00 120,400,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents -100,000.00 1,100,000.00 1,600,000.00 -4,400,000.00
Cash and cash equivalents 114,000,000.00 294,400,000.00 216,700,000.00 332,600,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

FI0009014369

LEI

74370029VAHCXDR7B745

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Nasdaq Helsinki

Stock Index

OMX Helsinki 25

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.